Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.

Quarter to September 2026, against a year earlier

132.05 3.93 +3.07%

Follow KYMR

Alert me

Kymera Therapeutics, Inc. 8-K filed Jul 27, 2026

Period ended Jul 27, 2026 · Filed Jul 27, 2026 · accepted 4:10 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

Red flags

Officer departure Jul 27, 2026
Kymera Therapeutics, Inc. reported the departure of an officer or director

8-K filed Jul 27, 2026 · The filing · sec.gov